Results: The effectiveness and risk–benefit profile of dopamine agonists and COMT inhibitors (as well as MAO-B-inhibitors) used as adjunctive therapy in PD patients with fluctuations were evaluated in a Cochrane meta-analysis in 2010 through an indirect comparison [61]. This evidence concerns the gene MAOB and Parkinson disease.